Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(21):1801-1803; doi:10.1093/jnci/91.21.1801
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 21, 1801-1803, November 3, 1999
© 1999 Oxford University Press

NEWS

Testicular Cancer Seen as "Stalking Horse" for Other Cancers

Brian Vastag

At first blush, putting more money into testicular cancer research may seem unnecessary. The long-term survival rate is high, and the number of new U.S. cases low, at 7,400 per year contrasted, for example, with 179,000 annual cases of prostate cancer.

However, the number of cases is increasing (see Stat Bite). And all cancer patients — not just young . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
C. Sturgeon
Practice Guidelines for Tumor Marker Use in the Clinic
Clin. Chem., August 1, 2002; 48(8): 1151 - 1159.
[Abstract] [Full Text] [PDF]